GET DAILY SIGNALSTriSalus Life Sciences (TLSI) Q3 2026: Revenue Growth Tempered by Guidance Cut
Key Takeaways
- TriSalus Life Sciences (TLSI) reported third quarter 2026 revenue of $12.9 million, up 11.3% year over year and about 13% sequentially, driven by TriNav adoption.
- Revenue and earnings per share (EPS) both missed consensus, with a net loss of $0.15 per share against expectations for a smaller loss.
- Gross margin improved to 86.2% from 83.5% a year earlier, while the operating loss narrowed to $7.7 million.
- Full-year 2026 revenue guidance was cut to $46 million–$48 million, down from the prior $54 million–$57 million range.
- The company received U.S. Food and Drug Administration (FDA) clearance for TriNav Advance, expanding its delivery technology to smaller vessels.
Earnings Context and Why It Matters
TriSalus Life Sciences is an oncology-focused medical technology company whose flagship TLSI TriNav Infusion System uses Pressure-Enabled Drug Delivery (PEDD) to deliver therapeutics directly into solid tumors. This quarterly earnings report matters because it tests whether the company's aggressive commercial expansion, which more than doubled its sales force earlier in 2026, is translating into revenue. After a weak first quarter and a modest second quarter, I was watching closely for a reacceleration in TriNav volumes. The report also carries broader implications: new FDA clearance for TriNav Advance and favorable 2027 Medicare reimbursement changes could reshape the company's growth runway, even as repeated guidance cuts have dented confidence in the near-term trajectory. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
TriSalus reported third quarter 2026 revenue of $12.9 million, up 11.3% from $11.6 million in the prior-year period and roughly 13% sequentially from $11.4 million in the second quarter. The result fell short of the approximately $14 million in consensus revenue, and the company's net loss of $0.15 per share was slightly wider than the roughly $0.14 loss analysts had expected.
Gross margin rose to 86.2% from 83.5% a year ago, reflecting lower production costs per TriNav unit. Operating loss narrowed to $7.7 million from $9.0 million, helped by lower research and development and administrative expenses, though sales and marketing spending increased to support the expanded field force. Net loss attributable to common stockholders was $8.9 million, down sharply from $41.3 million a year earlier, a comparison distorted by roughly $30.5 million in prior-year charges tied to preferred stock conversion. Adjusted EBITDA loss improved to $4.7 million from $5.4 million.
The company ended the quarter with $41.1 million in cash and cash equivalents.
Market Reaction and Investor Sentiment
Sentiment heading into the print was cautious after two consecutive quarters of softer-than-expected results, and the third quarter extended that streak. The revenue and EPS misses, combined with the third straight cut to full-year guidance, weighed on the stock in early trading. Investors appeared to focus less on the improving gross margin and narrowed operating loss, and more on the slower-than-anticipated ramp of newly hired sales representatives. The sequential revenue rebound and FDA clearance for TriNav Advance offered a partial offset, but the market's attention remained on whether management can convert an expanded commercial footprint into sustained, forecast-beating growth in 2027.
Forward Outlook and Key Factors to Monitor
The most important near-term development is the revised full-year 2026 revenue guidance of $46 million to $48 million, implying only about 2% to 6% growth compared with 2025. That marks a meaningful step down from the prior $54 million to $57 million range, which itself was lowered from an original $60 million to $62 million. Management attributed the shortfall primarily to slower sales representative productivity, particularly in newer expansion territories, and a faster-than-expected shift toward super-selective Y90 procedures in small distal vessels.
Investors should watch several catalysts heading into 2027. The limited market release of TriNav Advance, cleared by the FDA in September, is not yet contributing to fourth quarter guidance, so its broader launch will be a key growth lever. On the reimbursement side, changes from the Centers for Medicare & Medicaid Services (CMS) take effect January 1, 2027, including a higher national payment rate for certain hospital procedures and a new office-based payment arrangement that could open an additional channel.
Finally, the company expects initial data from the PROTECT registry on thyroid artery embolization in the first quarter of 2027, which could broaden the addressable market. With a cash balance of $41.1 million and continued investments in the commercial organization, the path to sustained double-digit growth and reduced cash burn will be central to investor sentiment in the quarters ahead. From what I see, these reimbursement updates stand out as particularly important.
Using Tickeron’s AI Screener for Deeper Analysis
In my view, Tickeron’s AI Screener has become a useful part of my routine when evaluating medical technology names like this one. It lets me quickly filter for technical patterns, fundamentals, and performance metrics across thousands of stocks and ETFs, surfacing relevant trade ideas and industry comparisons without manual effort. I find it especially helpful for spotting how TLSI stacks up against peers on volatility and trend signals, which adds context to the earnings picture and helps refine watchlist decisions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TLSI's Indicator enters downward trend
The Aroon Indicator for TLSI entered a downward trend on November 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 165 similar instances where the Aroon Indicator formed such a pattern. In 139 of the 165 cases the stock moved lower. This puts the odds of a downward move at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLSI as a result. In 57 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 59%.
The Moving Average Convergence Divergence Histogram (MACD) for TLSI turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 61 similar instances when the indicator turned negative. In 32 of the 61 cases the stock turned lower in the days that followed. This puts the odds of success at 52%.
The 50-day moving average for TLSI moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for TLSI's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +8.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLSI advanced for three days, in 136 of 212 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
TLSI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TLSI's P/B Ratio (30.552) is slightly higher than the industry average of (4.142). P/E Ratio (-2.444) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (5.459) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. TLSI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement